2022. Long-Term Safety and Disease Control of Ruxolitinib Cream Among Adolescents With Atopic Dermatitis: Results From Two Phase 3 Studies. SKIN The Journal of Cutaneous Medicine. 6, 2 (Mar. 2022), s28. DOI:https://doi.org/10.25251/skin.6.supp.28.